Search Result

Pathways Recommended:	MAPK/ERK Pathway

Results for "

p38 MAPK type II

" in MedChemExpress (MCE) Product Catalog:

By Targets:	p38 MAPK (3) Scavenger Receptor Class B type I (SR-BI） (2) Angiotensin Receptor (2)
By Research Areas:	Cardiovascular Disease (1) Endocrinology (2) Inflammation/Immunology (2) Neurological Disease (2)

Inhibitors & Agonists

Peptides

Targets Recommended: p38 MAPK Photosystem II MAP4K C-type Lectin-like Receptors (CTLRs) PCSK9 MAPKAPK2 (MK2) MNK CD74 Scavenger Receptor Class B type I (SR-BI）

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19900

ITX5061 3 Publications Verification	p38 MAPK Scavenger Receptor Class B type I (SR-BI）	Inflammation/Immunology
ITX5061 is an orally active type II non-competitive **p38 MAPK inhibitor. ITX5061 increases HDL-C levels by inhibiting SR-BI** activity. ITX5061 also moderately elevates ApoA-I levels. ITX5061 reduces early atherosclerotic lesions in the aortic arch of mice fed an atherogenic diet. ITX5061 can be used in the research of atherosclerosis .

HY-13106

Olodanrigan 4 Publications Verification EMA401; PD-126055; (S)-EMA400	Angiotensin Receptor	Cardiovascular Disease Neurological Disease Endocrinology
Olodanrigan (EMA401) is a highly selective, orally active, peripherally restricted *angiotensin II type* 2 receptor (AT2R)** antagonist. It is under development as a neuropathic pain therapeutic agent. Olodanrigan (EMA401) analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons .

HY-P10954

Link N peptide	p38 MAPK	Others
Link N peptide is a proteoglycan aggregates activator in the extracellular matrix. Link N peptide can selectively activate the p38 mitogen-activated protein kinase (MAPK) pathway to promote the expression of type I and II collagens in human intervertebral disc cells. Link N peptide is promising for research of intervertebral disc degeneration-related diseases .

HY-13106A

Olodanrigan sodium EMA401 sodium; PD-126055 sodium	Angiotensin Receptor	Neurological Disease Endocrinology
Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted *angiotensin II type* 2 receptor (AT2R)** antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons .

HY-122068

ITX5061 free base	p38 MAPK Scavenger Receptor Class B type I (SR-BI）	Inflammation/Immunology
ITX5061 free base is an orally active type II non-competitive **p38 MAPK inhibitor. ITX5061 free base increases HDL-C levels by inhibiting SR-BI** activity. ITX5061 free base also moderately elevates ApoA-I levels. ITX5061 free base reduces early atherosclerotic lesions in the aortic arch of mice fed an atherogenic diet. ITX5061 free base can be used in the research of atherosclerosis .

Cat. No.	Product Name	Target	Research Area

HY-P10954

Link N peptide	p38 MAPK	Others
Link N peptide is a proteoglycan aggregates activator in the extracellular matrix. Link N peptide can selectively activate the p38 mitogen-activated protein kinase (MAPK) pathway to promote the expression of type I and II collagens in human intervertebral disc cells. Link N peptide is promising for research of intervertebral disc degeneration-related diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.